furosemide has been researched along with Pulmonary Disease, Chronic Obstructive in 21 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aerosol furosemide may be an option to treat refractory dyspnea, though doses, methods of delivery, and outcomes have been variable." | 9.34 | Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients. ( Banzett, RB; Hallowell, RW; O'Donnell, CR; Schwartzstein, R; Sheridan, A, 2020) |
| "The aim of this study is to investigate the effects of inhaled furosemide on the sensation of dyspnea produced during exercise in patients with stable chronic obstructive pulmonary disease (COPD)." | 9.11 | Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. ( Chong, WF; Earnest, A; Kor, AC; Ong, KC; Wang, YT, 2004) |
| "Aerosol furosemide may be an option to treat refractory dyspnea, though doses, methods of delivery, and outcomes have been variable." | 5.34 | Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients. ( Banzett, RB; Hallowell, RW; O'Donnell, CR; Schwartzstein, R; Sheridan, A, 2020) |
| "The aim of this study is to investigate the effects of inhaled furosemide on the sensation of dyspnea produced during exercise in patients with stable chronic obstructive pulmonary disease (COPD)." | 5.11 | Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. ( Chong, WF; Earnest, A; Kor, AC; Ong, KC; Wang, YT, 2004) |
| "Furosemide is widely prescribed in patients with COPD for the treatment of peripheral edema." | 5.10 | Discontinuation of furosemide decreases PaCO(2) in patients with COPD. ( Brijker, F; Folgering, HT; Heijdra, YF; van den Elshout, FJ, 2002) |
| "The effective management of dyspnea in COPD remains a significant challenge for caregivers but recent treatment innovations such as helium-oxygen, inhaled furosemide and breathing feedback techniques have yielded early positive results." | 4.86 | Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. ( Jensen, D; O'Donnell, DE; Ora, J, 2010) |
| "We will identify all experimental studies using nebulised/inhaled furosemide in patients with asthma or chronic obstructive pulmonary disease that report any outcome." | 4.31 | Nebulised furosemide for the treatment of patients with obstructive lung disease: a systematic review protocol. ( Muscedere, J; Veldhoen, R, 2023) |
| "Forty patients with an AECOPD and high plasma BNP levels, but without any clinical evidence of cor pulmonale, were selected." | 2.77 | Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. ( Pan, X; Yu, X; Zhang, J; Zhao, G, 2012) |
| " Optimal dosing of opioids is being refined." | 2.44 | Pharmacological management of dyspnoea. ( Abernethy, AP; Currow, DC, 2007) |
| "Dyspnea in chronic obstructive pulmonary disease is clearly related to hyperinflation, and lung volumes are valuable for characterizing disease." | 2.44 | Mechanisms of dyspnea in chronic lung disease. ( Rock, LK; Schwartzstein, RM, 2007) |
| " This patient's case highlights the need of further studies evaluating efficacy of repeated dosing of CCP." | 1.62 | Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. ( Bloch, EM; Chua, F; Goel, R; Katz, LM; Mirihagalle, N; Parajuli, P; Prakash, V; Saha, D; Shah, A; Sundareshan, V; Tobian, AAR; Waqar, S, 2021) |
| "Normocapnic and chronic hypercapnic COPD patients have the same ventilatory and cerebrovascular carbon dioxide responsiveness irrespective of induced metabolic state." | 1.31 | Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD. ( Colier, WN; Folgering, H; Oeseburg, B; van de Ven, MJ; van der Sluijs, MC; Vis, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Veldhoen, R | 1 |
| Muscedere, J | 1 |
| Hallowell, RW | 1 |
| Schwartzstein, R | 1 |
| O'Donnell, CR | 1 |
| Sheridan, A | 1 |
| Banzett, RB | 1 |
| Syed, MP | 1 |
| Doshi, A | 1 |
| Pandey, D | 1 |
| Kate, Y | 1 |
| Harizi, R | 1 |
| Stingo, FE | 1 |
| Sallam, T | 1 |
| Govindu, R | 1 |
| Ammar, H | 1 |
| Mirihagalle, N | 1 |
| Parajuli, P | 1 |
| Sundareshan, V | 1 |
| Saha, D | 1 |
| Shah, A | 1 |
| Chua, F | 1 |
| Waqar, S | 1 |
| Prakash, V | 1 |
| Tobian, AAR | 1 |
| Bloch, EM | 1 |
| Katz, LM | 1 |
| Goel, R | 1 |
| Lee, G | 1 |
| Pickstone, N | 1 |
| Facultad, J | 1 |
| Titchener, K | 1 |
| Dotan, Y | 1 |
| Marchetti, N | 1 |
| Criner, GJ | 1 |
| Sheikh Motahar Vahedi, H | 2 |
| Mahshidfar, B | 2 |
| Rabiee, H | 2 |
| Saadat, S | 2 |
| Shokoohi, H | 2 |
| Chardoli, M | 2 |
| Rahimi-Movaghar, V | 2 |
| Hadda, V | 1 |
| Madan, K | 1 |
| Mohan, A | 1 |
| Ayub, II | 1 |
| Currow, DC | 1 |
| Abernethy, AP | 1 |
| Rock, LK | 1 |
| Schwartzstein, RM | 1 |
| Ora, J | 1 |
| Jensen, D | 2 |
| O'Donnell, DE | 2 |
| Prieto de Paula, JM | 1 |
| Franco Hidalgo, S | 1 |
| Borge Gallardo, L | 1 |
| Mayor Toranzo, E | 1 |
| Zhang, J | 1 |
| Zhao, G | 1 |
| Yu, X | 1 |
| Pan, X | 1 |
| Ong, KC | 1 |
| Kor, AC | 1 |
| Chong, WF | 1 |
| Earnest, A | 1 |
| Wang, YT | 1 |
| Kallet, RH | 1 |
| Amjadi, K | 1 |
| Harris-McAllister, V | 1 |
| Webb, KA | 1 |
| Cachia, E | 1 |
| Ahmedzai, SH | 1 |
| Brijker, F | 1 |
| Heijdra, YF | 1 |
| van den Elshout, FJ | 1 |
| Folgering, HT | 1 |
| van de Ven, MJ | 1 |
| Colier, WN | 1 |
| van der Sluijs, MC | 1 |
| Oeseburg, B | 1 |
| Vis, P | 1 |
| Folgering, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Outgoing Lung Team - a Cross-sectorial and Preventive Intervention in Patients at Risk of Hospitalisation Due to Exacerbation of COPD[NCT04119856] | 144 participants (Actual) | Interventional | 2017-09-25 | Completed | |||
| Brain During Effort : Effects of Hypoxia With Respiratory Patients[NCT02854280] | 33 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for furosemide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Pharmacological management of dyspnoea.
Topics: Analgesics, Opioid; Benzodiazepines; Drug Administration Routes; Dyspnea; Forced Expiratory Volume; | 2007 |
Mechanisms of dyspnea in chronic lung disease.
Topics: Clinical Trials as Topic; Dyspnea; Exercise Tolerance; Furosemide; Humans; Pulmonary Disease, Chroni | 2007 |
Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches.
Topics: Analgesics, Opioid; Dyspnea; Feedback, Physiological; Furosemide; Humans; Physical Exertion; Pulmona | 2010 |
The role of inhaled opioids and furosemide for the treatment of dyspnea.
Topics: Administration, Inhalation; Analgesics, Opioid; Dyspnea; Female; Furosemide; Humans; Male; Palliativ | 2007 |
6 trials available for furosemide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.
Topics: Administration, Inhalation; Adult; Aerosols; Aged; Aged, 80 and over; Asthma; Chronic Disease; Cross | 2020 |
The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial.
Topics: Administration, Inhalation; Aged; Blood Pressure; Bronchoconstriction; Diuretics; Dose-Response Rela | 2013 |
Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease.
Topics: Aged; Aminophylline; Bronchodilator Agents; Disease Progression; Drug Combinations; Female; Furosemi | 2012 |
Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aged; Anthropometry; Attitude to Health; Cross-Over Studies; Diuretics; | 2004 |
Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.
Topics: Administration, Inhalation; Adult; Aged; Cross-Over Studies; Double-Blind Method; Dyspnea; Exercise | 2008 |
Discontinuation of furosemide decreases PaCO(2) in patients with COPD.
Topics: Aged; Aged, 80 and over; Body Fluids; Carbon Monoxide; Cross-Over Studies; Diuretics; Double-Blind M | 2002 |
11 other studies available for furosemide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Nebulised furosemide for the treatment of patients with obstructive lung disease: a systematic review protocol.
Topics: Asthma; Bronchodilator Agents; Furosemide; Humans; Pulmonary Disease, Chronic Obstructive; Systemati | 2023 |
A rare case of biventricular non-compaction.
Topics: Cardiomyopathies; Carvedilol; Coronary Artery Disease; Dyspnea; Furosemide; Heart Failure; Heart Ven | 2020 |
It Is Not Pneumonia! A Case of Unilateral Pulmonary Edema.
Topics: Aged; Diagnosis, Differential; Female; Furosemide; Humans; Natriuretic Peptide, Brain; Peptide Fragm | 2021 |
Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient.
Topics: Anti-Bacterial Agents; Combined Modality Therapy; COVID-19; COVID-19 Serotherapy; Diabetes Mellitus, | 2021 |
The future of community nursing: Hospital in the Home.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Bronchodilator Agents; Clergy; Community Health Nursing; | 2017 |
Reexpansion Pulmonary Edema as a Complication of Endobronchial Valve Placement.
Topics: Aged; Bronchoscopy; Diuretics; Emphysema; Female; Furosemide; Humans; Oxyhemoglobins; Pulmonary Atel | 2017 |
Furosemide nebulization in patients with COPD exacerbation--reply.
Topics: Bronchoconstriction; Female; Furosemide; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2014 |
Furosemide Nebulization in Patients With COPD Exacerbation.
Topics: Bronchoconstriction; Female; Furosemide; Humans; Male; Pulmonary Disease, Chronic Obstructive | 2014 |
The importance of identifying the association between metabolic alkalosis and respiratory acidosis.
Topics: Acetazolamide; Acidosis, Respiratory; Alkalosis; Bicarbonates; Furosemide; Humans; Obesity Hypoventi | 2012 |
Breathlessness in cancer patients.
Topics: Administration, Inhalation; Analgesics, Opioid; Benzodiazepines; Bronchodilator Agents; Chemorecepto | 2008 |
Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD.
Topics: Acetazolamide; Administration, Oral; Alkalosis; Blood Volume; Carbon Dioxide; Cerebrovascular Circul | 2002 |